Eli Lilly's Q3 Blowout: Time to Buy LLY Stock?

💡 Key Takeaway

Eli Lilly's dominant position in the weight loss drug market and strong pipeline suggest the growth story is far from over, making the stock a compelling long-term buy despite its premium valuation.

Eli Lilly's Q3 Earnings: A Prescription for Growth

Eli Lilly reported third-quarter earnings that beat expectations, with revenue surging 39% to over $24 billion. The stellar performance was driven by its weight loss and diabetes drugs, Mounjaro and Zepbound, which saw sales jump 65% and 49%, respectively. The company also raised its full-year forecast, signaling confidence in continued momentum.

Lilly's weight loss portfolio has been a game-changer. The company now holds a commanding 63% share of the U.S. GLP-1 market, overtaking rival Novo Nordisk. The recent launch of Foundayo, an oral weight loss drug, has been well-received, with 40% of new patients opting for it and new patient numbers doubling from the previous quarter.

The stock has responded in kind, climbing about 27% this year and trading at a record high above $1,300. While the valuation at 42x forward earnings may seem steep, it's actually more reasonable than the 70x multiple seen in 2024.

Looking ahead, Lilly's pipeline includes retatrutide, a phase 3 candidate that has shown promising results for patients with greater weight loss needs. With only 3-10% of potential patients currently accessing weight loss care in the U.S., the room for expansion is dramatic, according to CEO David Ricks.

icon

What This Means for Me

If you hold LLY, the stock's momentum and strong fundamentals suggest continued upside, but be prepared for volatility given its high valuation. Investors with exposure to NVO should monitor competitive pressures, as Lilly's gains could come at Novo's expense. For those considering new positions, LLY offers a compelling growth story, but dollar-cost averaging could help mitigate entry point risk.

Why Lilly's Growth Story Still Has Legs

The weight loss drug market is far from saturated. With less than 10% penetration in the U.S., Lilly has a long runway for growth. The company's expanding portfolio, including oral options, could attract a broader patient population and drive further revenue gains.

Lilly's market share gains come at the expense of Novo Nordisk, which now holds a minority position. This competitive shift could pressure Novo's growth outlook while solidifying Lilly's leadership. Investors should watch for Novo's response, but for now, Lilly appears to have the upper hand.

The stock's premium valuation reflects high expectations, but Lilly's strong earnings growth and pipeline justify the multiple. As the company continues to innovate and expand access, the long-term growth trajectory remains intact.

While a near-term pullback is possible given the stock's run-up, any dip could be a buying opportunity. For long-term investors, Lilly offers a rare combination of defensive stability and high growth potential.

icon

Stock to Watch

StocksImpactAnalysis
LLY
Positive
Strong Q3 beat, raised guidance, and dominant market share in weight loss drugs position LLY for continued growth despite high valuation.

Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.

icon

Bobby Insight

bobby-insight

Eli Lilly remains a strong buy for long-term investors, even at record highs, given its market leadership and expansive growth opportunities.

The weight loss drug market is still in its early innings, and Lilly's innovative pipeline and market share gains provide a clear path to sustained growth. While the valuation is high, it's justified by the company's exceptional earnings growth and dominant position.

What This Means for Me

means-for-me
If you hold LLY, the stock's momentum and strong fundamentals suggest continued upside, but be prepared for volatility given its high valuation. Investors with exposure to NVO should monitor competitive pressures, as Lilly's gains could come at Novo's expense. For those considering new positions, LLY offers a compelling growth story, but dollar-cost averaging could help mitigate entry point risk.

Read More